JP6259831B2 - Ｃ型肝炎ウイルスに対するキメラワクチン抗原 - Google Patents

Ｃ型肝炎ウイルスに対するキメラワクチン抗原 Download PDF

Info

Publication number
JP6259831B2
JP6259831B2 JP2015540044A JP2015540044A JP6259831B2 JP 6259831 B2 JP6259831 B2 JP 6259831B2 JP 2015540044 A JP2015540044 A JP 2015540044A JP 2015540044 A JP2015540044 A JP 2015540044A JP 6259831 B2 JP6259831 B2 JP 6259831B2
Authority
JP
Japan
Prior art keywords
antigen
hcv
amino acids
chimeric
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015540044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536936A (ja
Inventor
カルレラ、サンティアゴ デュエニャス
カルレラ、サンティアゴ デュエニャス
ノリエガ、デイレン アギラル
ノリエガ、デイレン アギラル
カニサレス、ジャレナ アマドール
カニサレス、ジャレナ アマドール
− ラジョンセレ ポンセ デ レオン、リス アルヴァレス
− ラジョンセレ ポンセ デ レオン、リス アルヴァレス
ドナト、ジリアン マルティネス
ドナト、ジリアン マルティネス
ブランコ、ソニア ゴンサレス
ブランコ、ソニア ゴンサレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Genetic Engineering and Biotechnology
Original Assignee
Center for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Genetic Engineering and Biotechnology filed Critical Center for Genetic Engineering and Biotechnology
Publication of JP2015536936A publication Critical patent/JP2015536936A/ja
Application granted granted Critical
Publication of JP6259831B2 publication Critical patent/JP6259831B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015540044A 2012-11-05 2013-10-28 Ｃ型肝炎ウイルスに対するキメラワクチン抗原 Expired - Fee Related JP6259831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
CU2012-0153 2012-11-05
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (2)

Publication Number Publication Date
JP2015536936A JP2015536936A (ja) 2015-12-24
JP6259831B2 true JP6259831B2 (ja) 2018-01-10

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015540044A Expired - Fee Related JP6259831B2 (ja) 2012-11-05 2013-10-28 Ｃ型肝炎ウイルスに対するキメラワクチン抗原

Country Status (15)

Country Link
US (1) US9676825B2 (enExample)
EP (1) EP2915544B1 (enExample)
JP (1) JP6259831B2 (enExample)
KR (1) KR102093495B1 (enExample)
CN (1) CN104837498B (enExample)
AR (1) AR093341A1 (enExample)
AU (1) AU2013339846B2 (enExample)
CA (1) CA2901346C (enExample)
CU (1) CU24112B1 (enExample)
ES (1) ES2644801T3 (enExample)
IN (1) IN2015DN03925A (enExample)
MX (1) MX358507B (enExample)
RU (1) RU2639504C2 (enExample)
WO (1) WO2014067498A1 (enExample)
ZA (1) ZA201503036B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986342C (en) 2015-07-07 2024-04-02 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
AU2017332854B2 (en) 2016-09-21 2024-11-14 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
US11596679B2 (en) * 2017-04-27 2023-03-07 Vanderbilt University Hepatitis C virus gene sequences and methods of use therefor
CN112601548A (zh) * 2018-03-16 2021-04-02 艾伯塔大学理事会 丙型肝炎病毒肽组合物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039715D1 (de) 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
US20110110974A1 (en) 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
JP5593220B2 (ja) * 2008-04-25 2014-09-17 東レ株式会社 Ｃ型肝炎ウイルス由来のキメラ遺伝子を含む核酸
EP2331125A4 (en) * 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
IN2015DN03925A (enExample) 2015-10-02
KR102093495B1 (ko) 2020-03-26
US20150307558A1 (en) 2015-10-29
CU24112B1 (es) 2015-08-27
KR20150079694A (ko) 2015-07-08
EP2915544B1 (en) 2017-08-09
JP2015536936A (ja) 2015-12-24
AU2013339846B2 (en) 2017-08-17
MX358507B (es) 2018-08-22
US9676825B2 (en) 2017-06-13
MX2015005651A (es) 2015-08-20
CN104837498B (zh) 2018-05-18
CN104837498A (zh) 2015-08-12
CU20120153A7 (es) 2014-06-27
ES2644801T3 (es) 2017-11-30
CA2901346A1 (en) 2014-05-08
ZA201503036B (en) 2016-01-27
WO2014067498A1 (es) 2014-05-08
RU2639504C2 (ru) 2017-12-21
AR093341A1 (es) 2015-06-03
RU2015121429A (ru) 2016-12-27
AU2013339846A1 (en) 2015-05-14
EP2915544A1 (en) 2015-09-09
CA2901346C (en) 2019-04-23

Similar Documents

Publication Publication Date Title
Lechmann et al. Vaccine development for hepatitis C
Zingaretti et al. Why is it so difficult to develop a hepatitis C virus preventive vaccine?
EP1311289A2 (en) Vaccines containing ribavirin and methods of use thereof
AU2013339846B2 (en) Chimeric vaccine antigens against hepatitis C virus
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
KR101245154B1 (ko) 간염 ｃ 바이러스에 대한 백신 조성물
AU746258B2 (en) Genetic immunization with nonstructural proteins of hepatitis C virus
US20070032444A1 (en) Genetic immunization with nonstructural proteins of hepatitis C virus
JP2008508890A6 (ja) 組換え生鶏痘ウィルスベクター及びｃ型肝炎ウィルスに対する薬剤組成物中でのそれらの使用
HK1109069B (en) Vaccine composition against hepatitis c virus
JP2008508890A (ja) 組換え生鶏痘ウィルスベクター及びｃ型肝炎ウィルスに対する薬剤組成物中でのそれらの使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171211

R150 Certificate of patent or registration of utility model

Ref document number: 6259831

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees